Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial

Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000002963

Enrollment

Unknown

Registered

2020-02-03

Start date

2020-02-04

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

treament group:Chinese medicine decoction

placebo group:placebo

Eligibility

Sex/Gender

All

Age

14 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Conforming to the diagnostic criteria of suspected cases (Chiese medicine observation period) in the fourth edition of pneumonia diagnosis and treatment program for new coronavirus infection issued by the national health and health commission; (2) Age between 14 and 80 years old; (3) Patients informed and agreed to participate in the study.

Exclusion criteria

Exclusion criteria: (1) Patients are not suitable to take Chinese medicine decoction. (2) Patients have other serious organ disease or mental illness; (3) Patients allergy or have contraindications to the drugs involved in the research program.

Design outcomes

Primary

Measure	Time frame
Relief of clinical symptoms and duration;	—

Secondary

Measure	Time frame
Rate of severe pneumonia or death in people who progress to 2019-nCoV pneumonia;Progression rate of 2019-nCoV pneumonia;	—

Countries

China

Contacts

Public ContactChengping Wen

Zhejiang Chinese Medical University

wengcp@163.com+86 13601331063

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026